Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
US10934346B2 · kind B2 · utility
1Cited by
44References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 13, 2015 |
| Grant date | Mar 2, 2021 |
| Priority date | — |
| Expiry date | Jan 28, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.